Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-DART-NK02
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-DART-NK02 is an allogeneic, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech for the treatment of relapsed or refractory small cell lung cancer (SCLC). The therapy utilizes natural killer cells engineered to express CARs that simultaneously target Delta-like ligand 3 (DLL3) and Disialoganglioside GD2, both of which are frequently overexpressed in SCLC. This dual-targeting approach is designed to enhance tumor recognition and mitigate the risk of antigen escape, a common mechanism of resistance in single-target therapies. As an allogeneic product, EB-DART-NK02 is intended for "off-the-shelf" administration, potentially offering a more accessible and scalable alternative to autologous cell therapies. It is currently being evaluated in a Phase 1/2 adaptive dose-escalation and expansion study.
- Other names
- DLL3/GD2 CAR-NK cells
02
Targets
DLL3 (Delta-like ligand 3)GD2
Beyond the preview
Go deeper on EB-DART-NK02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-DART-NK02.